文献速递间质性肺疾病

脉冲甲泼尼龙联合低剂量泼尼松及他克莫司治疗结缔组织病相关间质性肺病的多维改善

Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus.
PubMed 文献 · Respirology · 2018-07-16

本回顾性病例系列纳入26例结缔组织病相关间质性肺病(CTD-ILD)患者,接受他克莫司联合静脉甲泼尼龙(1000 mg,每周3天,共2周)后低剂量泼尼松(10 mg/天)治疗。从基线至12个月,联合治疗显著改善用力肺活量、弥散功能、6分钟步行距离、运动最低血氧饱和度、MMRC评分和SGRQ评分,且耐受性良好。

要点

  • 联合治疗12个月显著改善FVC、DLCO、6MWD及最低SpO2。
  • MMRC和SGRQ评分亦显著改善,提示多维获益。
  • 仅1例因不良事件停药,无危及生命的不良事件。

核心结论

  • 脉冲甲泼尼龙后泼尼松联合他克莫司治疗CTD-ILD耐受性良好并有多维疗效。

研究设计与样本

  • 回顾性病例系列,连续纳入26例CTD-ILD患者。

主要发现

  • FVC从77.8%升至94.6%(P < 0.001)。
  • DLCO从66.1%升至75.1%(P < 0.001)。
  • 6MWD从530 m增至568 m(P = 0.02)。
  • 运动最低SpO2从85%升至89%(P = 0.01)。
  • MMRC从1.3降至0.8(P = 0.01),SGRQ从38降至21(P < 0.001)。

关键数值与推荐

  • 静脉甲泼尼龙1000 mg,每周3天,共2周。
  • 随后口服泼尼松10 mg/天,联合他克莫司。

临床怎么用

  • 对CTD-ILD患者可考虑脉冲甲泼尼龙后低剂量泼尼松联合他克莫司治疗。

局限性

  • 回顾性病例系列,样本量小,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Corticosteroids and immunosuppressive agents are considered mainstays of therapy for connective tissue disease-related interstitial lung disease (CTD-ILD); however, tacrolimus with corticosteroid therapy has not been fully investigated. Our objectives were to examine the multidimensional therapeutic benefit and tolerability of the combined therapy for the initial treatment of patients with CTD-ILD. METHODS: In this retrospective case series, we identified consecutive CTD-ILD patients treated with tacrolimus plus intravenous (i.v.) methylprednisolone (1000 mg i.v. 3 days a week for 2 weeks) followed by low-dose prednisolone (10 mg/day). We assessed the multidimensional therapeutic benefit and tolerability including lung physiology, exercise capacity, exercise oxygen desaturation, modified Medical Research Council (MMRC) and St George's Respiratory Questionnaire (SGRQ). RESULTS: A total of 26 ILD patients with the underlying CTD diagnoses included 11 with rheumatoid arthritis, 9 with dermatomyositis, 4 with Sjögren's syndrome and 2 others. From baseline to 12 months, the combined therapy significantly improved forced vital capacity (FVC; 77.8% to 94.6%, P < 0.001), diffusing capacity of the lung for carbon monoxide (DLCO ; 66.1% to 75.1%, P < 0.001), 6-min walk distance (6MWD; 530 to 568 m, P = 0.02), lowest oxygen saturation on pulse oximetry (SpO2 ; 85% to 89%, P = 0.01), MMRC (1.3 to 0.8, P = 0.01) and SGRQ (38 to 21, P < 0.001). During the study period, only one patient's therapy was discontinued due to an adverse event and none had a life-threatening adverse event attributed to the combined therapy. CONCLUSION: In our cohort of CTD-ILD, two courses of pulse dose methylprednisolone therapy followed by prednisone and oral tacrolimus appeared to be well tolerated, and to have multidimensional efficacy.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Yamano Y, Taniguchi H, Kondoh Y, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology. 2018. PMID: 30011421. doi:10.1111/resp.13365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。